For instance, HIF-1α inhibitors like PX-478 have demonstrated improvements in β-cell function within diabetic models, underscoring the therapeutic potential of modulating HIF-1α in diabetes and its complications [58]. This evidence concerns the gene HIF1A and diabetes mellitus.